Opinion

Video

Future Directions for Imaging and Biopsy in Prostate Cancer

Author(s):

David I. Lee, MD, FACS,Firas F. Abdollah, MD

The panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following questions:

      1. What clinical challenges and unmet needsremain regarding biopsy options in the diagnosis and management of patients with prostate cancer?
      2. What’s next? Are there any emerging technologies or data that you’re excited about in this area? Is there a role for fusion-guided biopsy with PSMA PET imaging in prostate cancer?
      3. Please share any closing thoughts or key takeaways regarding the use of fusion-guidedbiopsy in the diagnosis and management of prostate cancer?
      Related Videos
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
      Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
      Dr Louise Kostos answers a question during a Zoom video interview
      An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
      Rana McKay, MD, on the role of radium-223 in the modern era
      Rana McKay, MD, on the role of radium-223 in the modern era
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos discusses PSA kinetics in mHSPC
      Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC
      Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC
      Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
      The importance of PSADT in high-risk, biochemically recurrent prostate cancer
      Related Content
      3d rendered medically accurate illustration of prostate cancer | Image Credit: @ Sebastian Kaulitzki - stock.adobe.com
      April 15th 2025

      Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC

      Hannah Clarke
      The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: @ Dr_Microbe - stock.adobe.com
      April 10th 2025

      Polygenic risk score may identify more clinically significant PCa than PSA, MRI

      Hannah Clarke
      "Building on decades of research into the genetic markers of prostate cancer, our study shows that the theory does work in practice – we can identify men at risk of aggressive cancers who need further tests and spare the men who are at lower risk from unnecessary treatments," says Professor Ros Eeles.
      Dr. Schwen on focal therapies for prostate cancer
      January 11th 2024

      Dr. Schwen on focal therapies for prostate cancer

      Cleveland Clinic
      Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
      Genetic test can predict risk of toxicity following radiation for prostate cancer
      April 7th 2025

      Genetic test can predict risk of toxicity following radiation for prostate cancer

      Hannah Clarke
      "This finding reinforces PROSTOX ultra as a true measure of the biological response to radiation, independent of treatment era or technique that can identify the safest course of treatment to avoid toxicity," says Amar U. Kishan, MD.
      What urologists can expect in Q2 of 2025
      April 7th 2025

      What urologists can expect in Q2 of 2025

      Hannah Clarke Benjamin P. Saylor
      A lookahead of the notable FDA decisions and conferences slated for Q2 2025.
      © 2025 MJH Life Sciences

      All rights reserved.